Danish Novo Nordisk launched its blockbuster treatment injection Ozempic in three forms in 0.25 mg, 0.5 mg and 1 mg in the ...

The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines ...

Groundbreaking Harvard research reveals gut-produced molecules significantly influence obesity and blood sugar control. These ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

A cardiologist's assertion that Ozempic is a "cardiometabolic medicine" rather than just a weight-loss trend has sparked ...

The managing director of Novo Nordisk India on Ozempic’s delayed launch in India, leading the fight against diabetes and ...

Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...

MANY of us are about to embark on a whirlwind of festive events – most of which likely involve booze. And while we’re all ...

Weight-loss drugs have “little or no effect” on reducing the risk of cancers related to obesity, according to a new study.

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.

Just as the drug for type 2 diabetics does, it targets the brain’s reward pathways to reduce cravings. While Ozempic works to ...